Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01539473 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge
A Phase 1 study, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01539473 is a Phase 1 study that has completed, run by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 30 participants.
The verdict
NCT01539473, a Phase 1 study, has completed, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Phase 1 study to determine the effect of oral TR-701 FA on SBP response when administered with tyramine
Interventions
- DRUG TR-701 FA with Tyramine
- DRUG Placebo-controlled withTyramine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-02 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)18 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01539473
The ClinicalTrials.gov registry entry for NCT01539473 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TR-701 FA with Tyramine is the first listed.
NCT01539473 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01539473 about?
NCT01539473 is a clinical study titled "A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge". Phase 1 study to determine the effect of oral TR-701 FA on SBP response when administered with tyramine
What is the current status of trial NCT01539473?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2012-02. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01539473?
The interventions under investigation include: TR-701 FA with Tyramine (DRUG), Placebo-controlled withTyramine (DRUG).
Who is sponsoring clinical trial NCT01539473?
This trial is sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.